Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus MEGACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus MEGACE.
CURRETAB vs MEGACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian function and reduction of sex hormone levels. It also has antineoplastic effects through interference with estrogen receptor binding and may stimulate appetite via effects on neuropeptide Y and cytokines.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
Oral: 625 mg (suspension) or 400–800 mg (tablets) once daily.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal elimination half-life: 70-95 hours (mean 85 hours) in chronic dosing; shorter in initial doses; clinical context: requires 3-4 weeks to reach steady state.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Primarily renal: ~75% as glucuronide conjugates and unchanged drug; biliary/fecal: ~25% as metabolites.
Category C
Category C
Progestin
Progestin